Kindred Biosciences, Inc.
KIN
KIN was delisted on the 27th of August, 2021.
1 hedge funds and large institutions have $11K invested in Kindred Biosciences, Inc. in 2021 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 85 closing their positions.
100% more call options, than puts
Call options by funds: $2K | Put options by funds: $1K
99% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 85
99% less funds holding
Funds holding: 87 → 1 (-86)
100% less capital invested
Capital invested by funds: $280M → $11K (-$280M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CFO
CVA Family Office
Denver,
Colorado
|
+$23K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PWAM
Park West Asset Management
San Francisco,
California
|
-$55M |
| 2 |
Millennium Management
New York
|
-$25.2M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$17.3M |
| 4 |
Fidelity International
Hamilton,
Bermuda
|
-$16.6M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$14.9M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
76
Tower Research Capital (TRC)
New York
| – | -$51K | -5,575 | Closed |
|
|
CL
77
CSS LLC
Chicago,
Illinois
| – | -$50K | -5,500 | Closed |
|
|
BG
78
Bollard Group
Boston,
Massachusetts
| – | -$29K | -3,129 | Closed |
|
79
BNP Paribas Financial Markets
Paris,
France
| – | -$14.1K | -1,535 | Closed |
|
|
FCMT
80
Founders Capital Management (Texas)
Houston,
Texas
| – | -$14K | -1,500 | Closed |
|
|
PAM
81
Panagora Asset Management
Boston,
Massachusetts
| – | -$10K | -1,142 | Closed |
|
82
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| – | -$6K | -643 | Closed |
|
|
PA
83
Parallel Advisors
San Francisco,
California
| – | -$1K | -109 | Closed |
|
|
TWA
84
TCI Wealth Advisors
Tucson,
Arizona
| – | -$1K | -99 | Closed |
|
KIN Hedge Fund Activity: Q3 2021 in Review
1 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Kindred Biosciences, Inc. (KIN) for Q3 2021, worth a combined $11K — down 100% from $280M a quarter earlier.
Sellers outnumbered buyers: 85 funds closed out of KIN and 1 opened new positions — a net loss of 84 holders — while 0 trimmed existing stakes and 0 added.
The largest buyer was CVA Family Office, opening a new position worth an estimated $23K. The largest seller was Park West Asset Management, exiting entirely with an estimated $55M sold.
- 1 institutional investor held Kindred Biosciences, Inc. (KIN) as of Q3 2021, down from 87 in Q2 2021.
- Funds reported $11K of Kindred Biosciences, Inc. stock for Q3 2021, down 100% quarter-over-quarter.
- 1 fund opened new Kindred Biosciences, Inc. positions in Q3 2021 and 85 closed out, a net change of -84 holders.
- The largest Kindred Biosciences, Inc. buyer in Q3 2021 was CVA Family Office, an estimated $23K added.
- The largest Kindred Biosciences, Inc. seller in Q3 2021 was Park West Asset Management, an estimated $55M sold.
Based on aggregated 13F filings for Q3 2021.